Literature DB >> 9378463

GH treatment induces sustained catch-up growth in children with intrauterine growth retardation: 7-year results.

A Albanese1, R Stanhope.   

Abstract

The anthropometric response to 7 years of GH treatment was assessed in 11 short children with Russell-Silver syndrome (RSS) and in 5 with non-dysmorphic intrauterine growth retardation (NRSS). GH treatment induced a significant increase (p < 0.0001) in the mean height standard deviation score (SDS) and at the 7-year follow-up a height appropriate for the natural history of final stature in NRSS/RSS was already attained. An appreciable growth rate was still present with final height being attained only in 2 girls. There was no significant change in height SDS for bone age. Multiple regression analysis showed only chronological age at the onset of GH treatment was a predictor of gain in height SDS during GH therapy. These findings suggest that early GH treatment improves long-term growth in children with NRSS/RSS. Moreover, final height attainment is required for a definitive assessment of the beneficial effect on adult stature. Bone age assessment is not a reliable parameter to predict final height outcome in these children.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9378463     DOI: 10.1159/000185509

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  6 in total

1.  The spectrum of Silver-Russell syndrome: a clinical and molecular genetic study and new diagnostic criteria.

Authors:  S M Price; R Stanhope; C Garrett; M A Preece; R C Trembath
Journal:  J Med Genet       Date:  1999-11       Impact factor: 6.318

2.  IGF-I and IGF Binding Protein-3 Generation Tests and Response to Growth Hormone in Children with Silver-Russell Syndrome.

Authors:  Izabel C R Beserra; Márcia G Ribeiro; Paulo F Collett-Solberg; Mário Vaisman; Marília M Guimarães
Journal:  Int J Pediatr Endocrinol       Date:  2010-12-27

3.  Prediction models for short children born small for gestational age (SGA) covering the total growth phase. Analyses based on data from KIGS (Pfizer International Growth Database).

Authors:  Michael B Ranke; Anders Lindberg
Journal:  BMC Med Inform Decis Mak       Date:  2011-06-01       Impact factor: 2.796

4.  Height and body mass index in molecularly confirmed Silver-Russell syndrome and the long-term effects of growth hormone treatment.

Authors:  Oluwakemi Lokulo-Sodipe; Eloïse Giabicani; Ana P M Canton; Nawfel Ferrand; Jenny Child; Emma L Wakeling; Gerhard Binder; Irène Netchine; Deborah J G Mackay; Hazel M Inskip; Christopher D Byrne; I Karen Temple; Justin H Davies
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-21       Impact factor: 3.523

5.  Russell Silver syndrome: a perspective on growth and the influence of growth hormone therapy.

Authors:  J V Mascarenhas; Vageesh S Ayyar
Journal:  Indian J Endocrinol Metab       Date:  2012-09

6.  3-M syndrome associated with growth hormone deficiency: 18 year follow-up of a patient.

Authors:  Cristina Meazza; Ekkehard Lausch; Sara Pagani; Elena Bozzola; Valeria Calcaterra; Andrea Superti-Furga; Margherita Silengo; Mauro Bozzola
Journal:  Ital J Pediatr       Date:  2013-03-21       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.